Latest Breaking News On - Davidb mcwilliams - Page 1 : comparemela.com

STAFFORD, Texas (BUSINESS WIRE) Apr 10, 2021 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustain peak immunity, as well as to prevent metastatic breast cancer recurrences. Figures 1-3 of Poster Presentation CT183 from 2021 AACR Annual Meeting Showing GP2 5 Year Immune Response Data (Graphic: Business Wire)

United statesChristinet fischetteF joseph daughertyDavidb mcwilliamsMiras patelSnehals patelSnehal patelJaye thompsonGreenwich lifesciences incCompany contactRedchip companies incCompany twitterMd anderson cancer center phase iibPoster presentationMeeting showingImmune response data